Live Vaccine

## Rotavirus Vaccine Program Summary (Vaccine Code and Antigen Code: ROT-5)

Biological	Indications	Schedule	Specific Contraindications	Expected Reactions
<ul> <li>Rotavirus</li> <li>RotaTeq<sup>™</sup></li> <li>Manufacturer</li> <li>Merck Canada</li> <li>Includes G1, G2, G3, G4, P1A[8]8.</li> <li>Licensed from 6 weeks of age</li> <li>Alberta</li> <li>Health has approved an off-license completion schedule.</li> <li>Goal:</li> <li>95% series completed by 8 months of age.</li> <li>Program history:</li> <li>Rotavirus initiated June 1, 2015</li> <li>Rotarix<sup>™</sup> (Glaxo-Smith Kline) (ROT) June 1, 2015</li> <li>June 1, 2015</li> <li>June 1, 2015</li> <li>July 15, 2018</li> <li>RotaTeq<sup>™</sup> (Merck) (ROT-5) initiated May 14, 2018 to present.</li> </ul>	<ul> <li>Universal Program: Healthy infants starting immunization at 2 months of age.</li> <li>Notes: <ul> <li>Healthy, non-hospitalized preterm infants can receive this vaccine based on their chronological age.</li> <li>Infants with history of rotavirus gastroenteritis should complete the ROT series if eligible.</li> <li>Infants living in household with immunocompromised can receive the vaccine.</li> <li>Transplant recipients, contact CDC Team for direction.</li> <li>If two valid doses of <i>Rotarix</i> were received, the rotavirus series is complete. (Dose 1: two months of age, max. age 20 weeks. Dose 2: four months of age, min. 4 weeks after dose 1, and before 8 months age).</li> </ul> </li> </ul>	<ul> <li>RotaTeq (Merck) ROT-5:</li> <li>3 doses: 2, 4, and 6 months of age</li> <li>Administered orally: 2.0 mL</li> <li>Minimum spacing guidelines for</li> <li>RotaTeq<sup>™</sup> for infants off schedule:</li> <li>1<sup>st</sup> dose: Max. age 14 weeks and 6 days</li> <li>2<sup>nd</sup> dose: Minimum of 4 months of age and at least 4 weeks after 1<sup>st</sup> dose</li> <li>3<sup>rd</sup> dose: Minimum of 6 months of age and at least 4 weeks after 2<sup>nd</sup> dose.</li> <li>Dose must be administered before 8 calendar months of age.</li> <li>Notes:</li> <li>If the series was started with Rotarix, RotaTeq can be used to complete the series.</li> <li>If RotaTeq is used for any of the doses, a total of three doses of rotavirus vaccine should be administered as long as they continue to meet age and spacing criteria.</li> <li>Do not repeat dose in the event of infant spitting up or regurgitating vaccine.</li> <li>ROT can be administered with or at any time before or after live parenteral vaccines.</li> <li>If the first dose is given after the maximum age, consult CDC team.</li> <li>Parents should be informed about low risk of intussusception following rotavirus particularly 1<sup>st</sup> and 2<sup>nd</sup> dose. However, risk is small versus benefit of vaccine.</li> </ul>	<ul> <li>Contraindications:</li> <li>Infants less than 6 weeks of age or older than 8 months of age.</li> <li>Known sensitivity to any component of vaccine.</li> <li>History of anaphylactoid reaction to any previous dose of vaccine.</li> <li>Infants with a suspected or known immune compromising condition must have a consultation with the infant's physician/specialist prior to receiving the ROT vaccine.</li> <li>Infants with history of: <ul> <li>intussusception</li> <li>SCID (severe combined immunodeficiency disorder)</li> <li>uncorrected congenital GI tract disorders (eg. Meckel's diverticulum)</li> </ul> </li> <li>Infants with known or suspected family history of congenital/hereditary immunodeficiency that is a contraindication for live vaccine must have immune competency assessed by physician/specialist before ROT immunization.</li> <li>Infants of mothers who received immunosuppressive therapy during pregnancy or lactation. Consult CDC team for MOH evaluation.</li> </ul> Precautions: <ul> <li>Defer if acute febrile illness or moderate to severe diarrhea or vomiting is present.</li> <li>Immune-suppressive therapy given to a mother during pregnancy or breastfeeding can cause immunosuppression of infants, consult CDC team.</li> <li>Family to practice strict handwashing especially if in contact with immuno-compromised individuals.</li> </ul>	<ul> <li>Common: (1-9%)</li> <li>Fever, diarrhea and/or vomiting</li> <li>Irritability/fussiness</li> <li>Loss of appetite</li> <li>Cough/runny nose</li> <li>Otitis media</li> <li>Uncommon: (&lt;1%)</li> <li>Flatulence, abdominal pain</li> <li>Dermatitis</li> <li>Nasopharyngitis</li> <li>Bronchospasm</li> <li>Rare: (&lt;1/1000)</li> <li>Hematochezia (blood in stool)</li> <li>Intussusception (not confirmed – being closely monitored). Signs &amp; symptoms: signs of stomach pain along with severe crying, vomiting, blood in stool, weak or very irritable. May pull their legs up to their chest.</li> <li>Gastroenteritis</li> </ul>

Note:

• For oral use only - do not inject. Cold chain must be strictly observed. Vaccine must be protected from light.